GEN Exclusives

More »

GEN News Highlights

More »
Jan 5, 2007

BioVectra to Manufacture Helix’ Lung Cancer Candidate

  • Helix BioPharma signed an agreement with BioVectra to manufacture L-DOS47 bulk drug product for clinical testing in patients with adenocarcinoma of the lung. "BioVectra is a natural choice for our clinical manufacturing program requirements because in addition to their high calibre capabilities in the cGMP production of biopharmaceuticals, they are also one of the largest North American producers of the urease substance at the heart of our L-DOS47 drug product," notes John Docherty, Helix' vp of corporate development.

    During 2007, Helix intends to complete the remaining preclinical animal testing work with L-DOS47, in parallel with finalizing its clinical manufacturing activities.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?